Biotransformation in vitro: An essential consideration in the quantitative in vitro-to-in vivo extrapolation (QIVIVE) of toxicity data.
暂无分享,去创建一个
Sandra Coecke | Camilla Bernasconi | Iwona Wilk-Zasadna | Olavi Pelkonen | O. Pelkonen | S. Coecke | C. Bernasconi | I. Wilk-Zasadna
[1] Catarina Brito,et al. Human liver cell spheroids in extended perfusion bioreactor culture for repeated‐dose drug testing , 2012, Hepatology.
[2] F. Jordán,et al. Models of the ecological hierarchy : from molecules to the ecosphere , 2012 .
[3] Dennis A. Smith,et al. Evolution of ADME science: where else can modeling and simulation contribute? , 2013, Molecular pharmaceutics.
[4] Hugues Dolgos,et al. Utility of In Vitro Systems and Preclinical Data for the Prediction of Human Intestinal First-Pass Metabolism during Drug Discovery and Preclinical Development , 2013, Drug Metabolism and Disposition.
[5] Hans Clevers,et al. In vitro expansion of single Lgr5+ liver stem cells induced by Wnt-driven regeneration , 2013, Nature.
[6] Paolo Benedetti,et al. Exposition and reactivity optimization to predict sites of metabolism in chemicals. , 2013, Drug discovery today. Technologies.
[7] I. Wilson,et al. In vitro exploration of potential mechanisms of toxicity of the human hepatotoxic drug fenclozic acid , 2013, Archives of Toxicology.
[8] E. Testai,et al. The contribution of human small intestine to chlorpyrifos biotransformation. , 2012, Toxicology letters.
[9] T. Mauriala,et al. Mass spectrometric tools for cell and tissue studies. , 2012, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[10] Melvin E. Andersen,et al. Organotypic liver culture models: Meeting current challenges in toxicity testing , 2012, Critical reviews in toxicology.
[11] Roy J. Vaz,et al. The challenges of in silico contributions to drug metabolism in lead optimization , 2010, Expert opinion on drug metabolism & toxicology.
[12] P. Olinga,et al. Preparation and incubation of precision-cut liver and intestinal slices for application in drug metabolism and toxicity studies , 2010, Nature Protocols.
[13] A. Boobis,et al. Local Kinetics and Dynamics of Xenobiotics , 2008, Critical reviews in toxicology.
[14] Angus Nedderman,et al. Analytical strategies for identifying drug metabolites. , 2007, Mass spectrometry reviews.
[15] J. Houston,et al. Comparison of intrinsic clearances in human liver microsomes and suspended hepatocytes from the same donor livers: clearance-dependent relationship and implications for prediction of in vivo clearance , 2011, Xenobiotica; the fate of foreign compounds in biological systems.
[16] Benoît Schilter,et al. A physiologically based biokinetic (PBBK) model for estragole bioactivation and detoxification in rat. , 2008, Toxicology and applied pharmacology.
[17] Patricia Wright,et al. Metabolite identification by mass spectrometry: forty years of evolution , 2011, Xenobiotica; the fate of foreign compounds in biological systems.
[18] Andreas Bender,et al. Computational Prediction of Metabolism: Sites, Products, SAR, P450 Enzyme Dynamics, and Mechanisms , 2012, J. Chem. Inf. Model..
[19] T. Andersson,et al. Cytochrome P450-Dependent Metabolism in HepaRG Cells Cultured in a Dynamic Three-Dimensional Bioreactor , 2011, Drug Metabolism and Disposition.
[20] H. Toutain,et al. Precision-cut liver slices: characteristics and use for in vitro pharmaco-toxicology. , 2000, Toxicology.
[21] Harvey J Clewell,et al. PBTK modelling platforms and parameter estimation tools to enable animal-free risk assessment: recommendations from a joint EPAA--EURL ECVAM ADME workshop. , 2014, Regulatory toxicology and pharmacology : RTP.
[22] Hannu Raunio,et al. From known knowns to known unknowns: predicting in vivo drug metabolites. , 2009, Bioanalysis.
[23] P. Bachellier,et al. Plateable cryopreserved human hepatocytes for the assessment of cytochrome P450 inducibility: experimental condition-related variables affecting their response to inducers , 2012, Xenobiotica; the fate of foreign compounds in biological systems.
[24] U. Müller-Vieira,et al. Serum‐free culture of primary human hepatocytes in a miniaturized hollow‐fibre membrane bioreactor for pharmacological in vitro studies , 2015, Journal of Tissue Engineering and Regenerative Medicine.
[25] Sandra Coecke,et al. Three-dimensional HepaRG model as an attractive tool for toxicity testing. , 2012, Toxicological sciences : an official journal of the Society of Toxicology.
[26] P. Georgopoulos,et al. Tissue-Level Modeling of Xenobiotic Metabolism in Liver: An Emerging Tool for Enabling Clinical Translational Research , 2022 .
[27] Paavo Honkakoski,et al. Inhibition and induction of human cytochrome P450 enzymes: current status , 2008, Archives of Toxicology.
[28] A. Ahluwalia,et al. Modular bioreactor for primary human hepatocyte culture: Medium flow stimulates expression and activity of detoxification genes , 2011, Biotechnology journal.
[29] P. Maurel. Drug metabolizing enzymes , 1998 .
[30] J. Houston,et al. Evaluation of the novel in vitro systems for hepatic drug clearance and assessment of their predictive utility. , 2012, Toxicology in vitro : an international journal published in association with BIBRA.
[31] H. Tumen,et al. Pregnancy and chronic ulcerative colitis. , 1950, Gastroenterology.
[32] E. Bonnin,et al. An integrative in vitro approach to analyse digestion of wheat polysaccharides and the effect of enzyme supplementation , 2011, British Journal of Nutrition.
[33] Xavier Stéphenne,et al. Hepatocyte cryopreservation: is it time to change the strategy? , 2010, World journal of gastroenterology.
[34] Hyun Uk Kim,et al. Metabolite-centric approaches for the discovery of antibacterials using genome-scale metabolic networks. , 2010, Metabolic engineering.
[35] Francesca Caloni,et al. Caco-2/TC7 cell line characterization for intestinal absorption: how reliable is this in vitro model for the prediction of the oral dose fraction absorbed in human? , 2011, Toxicology in vitro : an international journal published in association with BIBRA.
[36] Thomas A. Louis,et al. The Future Use of in Vitro Data in Risk Assessment to Set Human Exposure Standards: Challenging Problems and Familiar Solutions , 2010, Environmental health perspectives.
[37] Harvey J Clewell,et al. Relative impact of incorporating pharmacokinetics on predicting in vivo hazard and mode of action from high-throughput in vitro toxicity assays. , 2013, Toxicological sciences : an official journal of the Society of Toxicology.
[38] Ursula Gundert-Remy,et al. Physiologically-based Kinetic Modelling (PBK Modelling): Meeting the 3Rs Agenda , 2007, Alternatives to laboratory animals : ATLA.
[39] O. Pelkonen,et al. Analytical challenges for conducting rapid metabolism characterization for QIVIVE. , 2015, Toxicology.
[40] F. Russel,et al. Semi-mechanistic physiologically-based pharmacokinetic modeling of clinical glibenclamide pharmacokinetics and drug-drug-interactions. , 2013, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[41] W. Dekant. The role of biotransformation and bioactivation in toxicity. , 2009, EXS.
[42] F. Williams. Potential for metabolism locally in the skin of dermally absorbed compounds , 2008, Human & experimental toxicology.
[43] Sandra Coecke,et al. Comparison of metabolic stability and metabolite identification of 55 ECVAM/ICCVAM validation compounds between human and rat liver homogenates and microsomes - a preliminary analysis. , 2009, ALTEX.
[44] C. Yap,et al. Pharmaceutical metabolite profiling using quadrupole/ion mobility spectrometry/time-of-flight mass spectrometry. , 2009, Rapid communications in mass spectrometry : RCM.
[45] Takanori Takebe,et al. Vascularized and functional human liver from an iPSC-derived organ bud transplant , 2013, Nature.
[46] K. Brouwer,et al. Sandwich-cultured hepatocytes: an in vitro model to evaluate hepatobiliary transporter-based drug interactions and hepatotoxicity , 2010, Drug metabolism reviews.
[47] John C Lipscomb,et al. Scaling factors for the extrapolation of in vivo metabolic drug clearance from in vitro data: reaching a consensus on values of human microsomal protein and hepatocellularity per gram of liver. , 2007, Current drug metabolism.
[48] Arnaud Tonnelier,et al. Screening of chemicals for human bioaccumulative potential with a physiologically based toxicokinetic model , 2011, Archives of Toxicology.
[49] A. Guillouzo,et al. Functional expression, inhibition and induction of CYP enzymes in HepaRG cells. , 2009, Toxicology in vitro : an international journal published in association with BIBRA.
[50] F. Guengerich. Cytochrome p450 and chemical toxicology. , 2008, Chemical research in toxicology.
[51] Robert J Kavlock,et al. Integration of dosimetry, exposure, and high-throughput screening data in chemical toxicity assessment. , 2012, Toxicological sciences : an official journal of the Society of Toxicology.
[52] Yuko Ito,et al. Human CYPs involved in drug metabolism: structures, substrates and binding affinities , 2010, Expert opinion on drug metabolism & toxicology.
[53] Mingshe Zhu,et al. Recent advances in applications of liquid chromatography-tandem mass spectrometry to the analysis of reactive drug metabolites. , 2009, Chemico-biological interactions.
[54] Adam S. Hayward,et al. Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME , 2013, Archives of Toxicology.
[55] Bruno Sarmento,et al. Models to predict intestinal absorption of therapeutic peptides and proteins. , 2012, Current drug metabolism.
[56] Andrew Worth,et al. Metabolism: A Bottleneck in In Vitro Toxicological Test Development , 2006, Alternatives to laboratory animals : ATLA.
[57] Richard S. Judson,et al. Modeling In Vitro Cell-Based Assays Experiments: Cell Population Dynamics , 2012 .
[58] Urs A Meyer,et al. Omics and drug response. , 2013, Annual review of pharmacology and toxicology.
[59] O. Pelkonen,et al. Hepatocytes: the powerhouse of biotransformation. , 2012, The international journal of biochemistry & cell biology.
[60] M. Monshouwer,et al. Determination of Time-Dependent Inactivation of CYP3A4 in Cryopreserved Human Hepatocytes and Assessment of Human Drug-Drug Interactions , 2011, Drug Metabolism and Disposition.
[61] Alessandro Pedretti,et al. Reactions and enzymes in the metabolism of drugs and other xenobiotics. , 2012, Drug discovery today.
[62] J Brian Houston,et al. Evaluation of Cryopreserved Human Hepatocytes as an Alternative in Vitro System to Microsomes for the Prediction of Metabolic Clearance , 2007, Drug Metabolism and Disposition.
[63] Hung-Chih Kuo,et al. Rapid generation of mature hepatocyte‐like cells from human induced pluripotent stem cells by an efficient three‐step protocol , 2012, Hepatology.
[64] P. Bachellier,et al. Inter-laboratory evaluation of the response of primary human hepatocyte cultures to model CYP inducers - a European Centre for Validation of Alternative Methods (ECVAM) - funded pre-validation study. , 2010, Toxicology in vitro : an international journal published in association with BIBRA.
[65] A. Vickers,et al. Organ slices for the evaluation of human drug toxicity. , 2004, Chemico-biological interactions.
[66] P. Alves,et al. Towards an extended functional hepatocyte in vitro culture. , 2009, Tissue engineering. Part C, Methods.
[67] J. Venitz,et al. Preclinical Disposition (In Vitro) of Novel μ-Opioid Receptor Selective Antagonists , 2011, Drug Metabolism and Disposition.
[68] Ian D. Wilson,et al. Managing the challenge of chemically reactive metabolites in drug development , 2011, Nature Reviews Drug Discovery.
[69] Carl-Fredrik Mandenius,et al. Toward Preclinical Predictive Drug Testing for Metabolism and Hepatotoxicity by Using In Vitro Models Derived from Human Embryonic Stem Cells and Human Cell Lines — A Report on the Vitrocellomics EU-project , 2011, Alternatives to laboratory animals : ATLA.
[70] Hiroshi Yamazaki,et al. Methodologies for investigating drug metabolism at the early drug discovery stage: prediction of hepatic drug clearance and P450 contribution. , 2010, Current drug metabolism.
[71] O. Pelkonen,et al. Rapid detection and characterization of reactive drug metabolites in vitro using several isotope-labeled trapping agents and ultra-performance liquid chromatography/time-of-flight mass spectrometry. , 2009, Rapid communications in mass spectrometry : RCM.
[72] M. Ierapetritou,et al. Analysis of amino acid supplementation effects on hepatocyte cultures using flux balance analysis. , 2011, Omics : a journal of integrative biology.
[73] S. Haddad,et al. Toward a new paradigm for the efficient in vitro-in vivo extrapolation of metabolic clearance in humans from hepatocyte data. , 2013, Journal of pharmaceutical sciences.
[74] Harvey J Clewell,et al. Quantitative in vitro to in vivo extrapolation of cell-based toxicity assay results , 2012, Critical reviews in toxicology.
[75] Yan Li,et al. Risk assessment and mitigation strategies for reactive metabolites in drug discovery and development. , 2011, Chemico-biological interactions.
[76] Bas J Blaauboer,et al. The contribution of in vitro toxicity data in hazard and risk assessment: current limitations and future perspectives. , 2008, Toxicology letters.
[77] André Guillouzo,et al. The human hepatoma HepaRG cells: a highly differentiated model for studies of liver metabolism and toxicity of xenobiotics. , 2007, Chemico-biological interactions.
[78] M. Schwab,et al. Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation , 2008, Analytical and bioanalytical chemistry.
[79] Klaus Mauch,et al. A Multi-Scale Modeling Framework for Individualized, Spatiotemporal Prediction of Drug Effects and Toxicological Risk , 2013, Front. Pharmacol..
[80] J. Castro-Pérez,et al. High-resolution chromatography/time-of-flight MSE with in silico data mining is an information-rich approach to reactive metabolite screening. , 2011, Rapid communications in mass spectrometry : RCM.
[81] Claus-Michael Lehr,et al. An in vitro triple cell co-culture model with primary cells mimicking the human alveolar epithelial barrier. , 2011, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[82] O. Hovatta,et al. Improved cryopreservation of human hepatocytes using a new xeno free cryoprotectant solution. , 2012, World journal of hepatology.
[83] D. Goldstein,et al. CYP2C9*1B Promoter Polymorphisms, in Linkage with CYP2C19*2, Affect Phenytoin Autoinduction of Clearance and Maintenance Dose , 2010, Journal of Pharmacology and Experimental Therapeutics.
[84] Thomas Schreiter,et al. Scaling down of a clinical three-dimensional perfusion multicompartment hollow fiber liver bioreactor developed for extracorporeal liver support to an analytical scale device useful for hepatic pharmacological in vitro studies. , 2011, Tissue engineering. Part C, Methods.
[85] Valérie Zuang,et al. Alternative (non-animal) methods for cosmetics testing: current status and future prospects—2010 , 2011, Archives of Toxicology.
[86] M. Ingelman-Sundberg,et al. Tumour-specific expression of CYP2W1: its potential as a drug target in cancer therapy , 2007, Expert opinion on therapeutic targets.
[87] Ismael Zamora,et al. Enhanced metabolite identification with MS(E) and a semi-automated software for structural elucidation. , 2010, Rapid communications in mass spectrometry : RCM.
[88] L. Wienkers,et al. Application of cytochrome P450 drug interaction screening in drug discovery. , 2010, Combinatorial chemistry & high throughput screening.
[89] Ugo Zanelli,et al. Comparison of Cryopreserved HepaRG Cells with Cryopreserved Human Hepatocytes for Prediction of Clearance for 26 Drugs , 2012, Drug Metabolism and Disposition.
[90] P. Nieminen,et al. Estimation of health risk by using toxicokinetic modelling: a case study of polychlorinated biphenyl PCB153. , 2013, Journal of hazardous materials.
[91] O. Pelkonen,et al. In vitro–in vivo extrapolation of hepatic clearance: Biological tools, scaling factors, model assumptions and correct concentrations , 2007, Xenobiotica; the fate of foreign compounds in biological systems.
[92] E. Testai,et al. Caco 2/TC7 cell line chracterization for intestinal absorption : a reliable in vitro model for the prediction of the oral dose fraction absorbed in human , 2008 .
[93] J. Houston,et al. Prediction of Human Metabolic Clearance from In Vitro Systems: Retrospective Analysis and Prospective View , 2010, Pharmaceutical Research.
[94] A. Taniguchi,et al. [Development of novel culture system using nano-biotechnology]. , 2010, Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan.
[95] Haishan Wang,et al. Preclinical Metabolism and Disposition of SB939 (Pracinostat), an Orally Active Histone Deacetylase Inhibitor, and Prediction of Human Pharmacokinetics , 2011, Drug Metabolism and Disposition.
[96] A. Guillouzo,et al. Running title page Running title : Functional stability of CYP P 450 enzymes in HepaRG cells , 2009 .
[97] Z. Dvořák,et al. Rifampicin Does not Significantly Affect the Expression of Small Heterodimer Partner in Primary Human Hepatocytes , 2011, Front. Pharmacol..
[98] K. Vähäkangas,et al. Preservation, induction or incorporation of metabolism into the in vitro cellular system - views to current opportunities and limitations. , 2013, Toxicology in vitro : an international journal published in association with BIBRA.
[99] Bas J Blaauboer,et al. The use of biomarkers of toxicity for integrating in vitro hazard estimates into risk assessment for humans. , 2012, ALTEX.
[100] T. Rushmore,et al. Cytotoxicity of 3-(3,5-dichlorophenyl)-2,4-thiazolidinedione (DCPT) and analogues in wild type and CYP3A4 stably transfected HepG2 cells. , 2011, Toxicology in vitro : an international journal published in association with BIBRA.
[101] J Scheel,et al. Report from the EPAA workshop: in vitro ADME in safety testing used by EPAA industry sectors. , 2011, Toxicology in vitro : an international journal published in association with BIBRA.
[102] Chuang Lu,et al. The Conduct of in Vitro Studies to Address Time-Dependent Inhibition of Drug-Metabolizing Enzymes: A Perspective of the Pharmaceutical Research and Manufacturers of America , 2009, Drug Metabolism and Disposition.
[103] J. Ambroso,et al. Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds. , 2012, Chemical research in toxicology.
[104] S. Krähenbühl,et al. The role of CYP3A4 in amiodarone-associated toxicity on HepG2 cells. , 2011, Biochemical pharmacology.
[105] Carolyn Vickers,et al. Risk assessment of combined exposure to multiple chemicals: A WHO/IPCS framework. , 2011, Regulatory toxicology and pharmacology : RTP.
[106] Bruno Sarmento,et al. Cell-based in vitro models for predicting drug permeability , 2012, Expert opinion on drug metabolism & toxicology.
[107] D. Howes,et al. Percutaneous penetration and dermal metabolism of triclosan (2,4, 4'-trichloro-2'-hydroxydiphenyl ether). , 2000, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.
[108] Jörg C Gerlach,et al. HepaRG human hepatic cell line utility as a surrogate for primary human hepatocytes in drug metabolism assessment in vitro. , 2011, Journal of pharmacological and toxicological methods.
[109] J. Sahi,et al. Hepatocytes as a tool in drug metabolism, transport and safety evaluations in drug discovery. , 2010, Current drug discovery technologies.
[110] Amin Rostami-Hodjegan,et al. Simulation and prediction of in vivo drug metabolism in human populations from in vitro data , 2007, Nature Reviews Drug Discovery.
[111] M. Schwab,et al. Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. , 2013, Pharmacology & therapeutics.
[112] George Loizou,et al. Toxicokinetics as a key to the integrated toxicity risk assessment based primarily on non-animal approaches. , 2013, Toxicology in vitro : an international journal published in association with BIBRA.
[113] M. Vidyavathi,et al. Role of Human Liver Microsomes in In Vitro Metabolism of Drugs—A Review , 2010, Applied biochemistry and biotechnology.
[114] T. Baillie,et al. Metabolism and toxicity of drugs. Two decades of progress in industrial drug metabolism. , 2008, Chemical research in toxicology.
[115] J. Mak,et al. In vitro approaches to investigate cytochrome P450 activities: update on current status and their applicability , 2013, Expert opinion on drug metabolism & toxicology.
[116] S. Reichl,et al. Cultivation of RPMI 2650 cells as an in‐vitro model for human transmucosal nasal drug absorption studies: optimization of selected culture conditions , 2012, The Journal of pharmacy and pharmacology.
[117] C. Lehr,et al. A new Pharmaceutical Aerosol Deposition Device on Cell Cultures (PADDOCC) to evaluate pulmonary drug absorption for metered dose dry powder formulations. , 2011, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[118] Alicia Paini,et al. In vivo validation of DNA adduct formation by estragole in rats predicted by physiologically based biodynamic modelling. , 2012, Mutagenesis.
[119] F. Sonntag,et al. A dynamic multi-organ-chip for long-term cultivation and substance testing proven by 3D human liver and skin tissue co-culture. , 2013, Lab on a chip.
[120] L. Ståhle,et al. Assessment of interaction potential of AZD2066 using in vitro metabolism tools, physiologically based pharmacokinetic modelling and in vivo cocktail data , 2013, European Journal of Clinical Pharmacology.
[121] M. Ierapetritou,et al. A Rational Design Approach for Amino Acid Supplementation in Hepatocyte Culture , 2009 .
[122] P. Prusis,et al. Evaluation of the human prediction of clearance from hepatocyte and microsome intrinsic clearance for 52 drug compounds , 2010, Xenobiotica; the fate of foreign compounds in biological systems.
[123] Tommy B Andersson,et al. Evaluation of HepaRG Cells as an in Vitro Model for Human Drug Metabolism Studies , 2008, Drug Metabolism and Disposition.
[124] Y. Wong,et al. Pharmacokinetic characterization of a natural product–inspired novel MEK1 inhibitor E6201 in preclinical species , 2011, Cancer Chemotherapy and Pharmacology.
[125] Bas J Blaauboer,et al. Biokinetic Modeling and in Vitro–in Vivo Extrapolations , 2010, Journal of toxicology and environmental health. Part B, Critical reviews.
[126] Bálint Sinkó,et al. Skin-PAMPA: a new method for fast prediction of skin penetration. , 2012, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[127] P. Olinga,et al. Liver slices in in vitro pharmacotoxicology with special reference to the use of human liver tissue. , 1997, Toxicology in vitro : an international journal published in association with BIBRA.